Brief: Diasorin Obtains FDA 510(K) Clearance For Its Liaison Plex Yeast Blood Culture Assay
05/06/2024 09:25
June 5 (Reuters) - DiaSorin SpA DIAS.MI :
* OBTAINS FDA 510(K) CLEARANCE FOR ITS LIAISON PLEX® YEAST
BLOOD
CULTURE ASSAY, FOLLOWING LIAISON PLEX SYSTEM CLEARANCE IN MARCH
Further company coverage: DIAS.MI
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on DiaSorin SpA
See all newsKepler sees European Medtech recovery, starts BioMerieux at 'Buy' as top pick
Brief: Diasorin Receives Us' FDA 510(K) Clearance And Clia Waiver For Liaison Nes Group A Streptococcus (Gas) Assay
Deutsche Bank cuts Diasorin to 'sell', sees company targets as stretched
Italy - Factors to watch on June 5
Italy's DiaSorin jumps after Betaville reports possible takeover interest